logo-loader
Imugene Ltd

Imugene to acquire exclusive licence for potentially transformational oncolytic virus technology

A phase-one clinical trial in 30 patients with advanced tumours is expected to start in 2020 across a number of US cancer centres.

1563156762_hepb.jpg
Preclinical data has demonstrated CF33 more efficacious than all parental viruses and some viruses in clinical trials

Imugene Ltd (ASX:IMU) (OTCMKTS:IUGNF) is to acquire the worldwide exclusive licence to oncolytic virus technology known as CF33.

Development and commercialisation of CF33, a chimeric vaccinia poxvirus, will be funded through Imugene’s existing cash reserves and will include ex-Viralytics members as part of its project development team.

 

Imugene chief executive officer Leslie Chong said the company was delighted to licence such a promising next-generation oncolytic virus (OV) in a competitive marketplace, where big pharma companies are actively seeking OV technologies.

Oncolytic viruses are designed to both selectively kill tumours cells and activate the immune system against cancer cells, with the potential to improve clinical response and survival.

The viruses have the potential to transform oncology by directly causing tumour cell death and also by delivering a potent payload in a targeted fashion that activates the immune system.

READ: Imugene reveals new clinical data for HER-Vaxx vaccine showing cancer-fighting response

Chong continued: “CF33 comes with robust intellectual property and long patent life, compelling pre-clinical efficacy and safety and is anticipated to enter a phase-one clinical trial in 2020.

“The opportunity to separately engage with members of the ex-Viralytics team through Vaxinia was cogent for immune.

“[It] bring to Imugene senior executives with direct involvement in two of the largest OV transaction in biotech history being Amgen’s acquisition of Biovex for US$950 million and Merck’s acquisition of Viralytics for A$502 million.”

READ: Imugene presents new HER-Vaxx cancer vaccine results

The drug was initially developed at Los Angeles-based City of Hope, a world-renowned independent research and treatment centre for cancer, diabetes and other life-threatening diseases.

In consideration for the exclusive licence, City of Hope will receive from Imugene licence fees comprising an upfront, annual maintenance fee creditable against future royalty payments.

The company will also pay performance-based consideration linked to achieving certain milestones and commercial outcomes, as well as net sales-based royalty payments and sub-licencing fees.

READ: Imugene well-funded to progress clinical milestones

As part of the transaction, Imugene entered into a binding agreement to acquire 100% of Vaxinia, of which Imugene executive chairman Paul Hopper is major shareholder.

The transaction includes an up-front cash payment of A$462,500 and the issue of ordinary fully paid Imugene shares valued at A$1.619 million, based on the seven-day volume weighted average price.

The decision to acquire Vaxinia was made by Imugene’s independent directors, with Hopper recused from the process given he is a beneficiary of the transaction.

READ: Imugene presents positive new data validating its human cancer vaccine KEY-Vaxx

Shareholders of Vaxinia include, along with Hopper, City of Hope chair of surgery Professor Yuman Fong, the inventor of CF33, and an ex-Viralytics executive.

They will be eligible for further payments in equity on the achievement of performance-related milestones.

These milestones will be further detailed in the company’s notice to meeting and will include granting of investigational new drug status by the Federal Drug Administration (FDA), dosing the first patient in a phase-one clinical trial and the phase-one clinical trial demonstrating safety.

Quick facts: Imugene Ltd

Price: $0.02

Market: ASX
Market Cap: $83.03 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Imugene Ltd named herein, including the promotion by the Company of Imugene Ltd in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Imugene Limited releases new clinical data for HER-Vaxx cancer vaccine study

Imugene Limited (ASX:IMU) chief executive officer Leslie Chong updates Proactive Investors on new clinical data from the Phase 1b study of its HER-Vaxx cancer vaccine after presenting at the European Society for Medical Oncology World Congress on gastrointestinal cancer in Spain over the...

on 8/7/19

3 min read